• EU approval is based on two Phase III studies showing Cosentyx^® provides fast and strong skin clearance, along with significant improvement in quality of life and a favorable safety profile¹
   
• Moderate-to-severe psoriasis affects more than 350,000 children worldwide², with the physical and psychological burden disrupting important formative years³
   
• Cosentyx is a proven brand, supported by long-term five-year sustained efficacy and safety data across psoriasis, psoriatic arthritis ( …